FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385803022> ?p ?o ?g. }

• W4385803022 abstract "Abstract To explore the effect of IL-6 on the activity and secretory function of B cells and analyze its effect on clinical indicators and efficacy in wAIHA patients. This study included 25 hemolytic wAIHA patients, 13 remission patients, and 10 HCs. Plasma levels of various cytokines were detected using CBA. PBMCs were extracted from 12 hemolytic wAIHA patients and divided into three wells, stimulation with IL-6 and IL-6 + tocilizumab, the blank control wells were also set. After 48 h of in vitro cell culture, percentage of CD5 + CD80 + , CD5 – CD80 + ,CD5 + CD86 + ,CD5 – CD86 + ,CD5 + IL-10 + ,CD5 – IL-10 + B cells were determined by flow-cytometry. Plasma levels of IL-6 and IL-10 in hemolytic episode group were significantly higher than that in HCs group ( p = 0.0243; p = 0.0214). RBC and Hb levels were negatively correlated with IL-6 levels in wAIHA patients, while LDH levels were positively correlated.Therapeutic effects of glucocorticoid and duration of efficacy were also significantly correlated with IL-6 levels in wAIHA patients. After 48 h in vitro cell culture, percentages of CD80 + /CD5 + CD19 + and CD80 + /CD5 – CD19 + cells in the IL-6 stimulation group were higher than those in blank control group ( p = 0.0019; p = 0.0004), while CD86 + /CD5 + CD19 + and CD86 + /CD5 – CD19 + cells were not statistically different before and after IL-6 stimulation. Percentage of IL-10 + /CD5 + CD19 + cells in IL-6 stimulation group was lower than that in blank control ( p = 0.0017) and IL-6 + toc ( p = 0.0117) group. Percentage of IL-10 + /CD5 – CD19 + cells in the IL-6 stimulation group was lower than that in the blank control group ( p = 0.0223). Plasma levels of IL-6 were significantly elevated in hemolytic wAIHA patients and correlated with clinical indicators and efficacy. IL-6 promotes the activation of B cells. Although the results were not statistically significant, IL-6R antagonist tocilizumab may hopefully become a targeted therapy for wAIHA patients." @default.
• W4385803022 created "2023-08-15" @default.
• W4385803022 creator A5005059937 @default.
• W4385803022 creator A5010738468 @default.
• W4385803022 creator A5029839968 @default.
• W4385803022 creator A5032499914 @default.
• W4385803022 creator A5034185369 @default.
• W4385803022 creator A5035457024 @default.
• W4385803022 creator A5040485869 @default.
• W4385803022 creator A5077389488 @default.
• W4385803022 date "2023-08-14" @default.
• W4385803022 modified "2023-10-17" @default.
• W4385803022 title "Interleukin 6 exacerbates the progression of warm autoimmune hemolytic anemia by influencing the activity and function of B cells" @default.
• W4385803022 cites W1963721921 @default.
• W4385803022 cites W1974356658 @default.
• W4385803022 cites W1976949503 @default.
• W4385803022 cites W2006236831 @default.
• W4385803022 cites W2013352098 @default.
• W4385803022 cites W2019325157 @default.
• W4385803022 cites W2060914801 @default.
• W4385803022 cites W2067384298 @default.
• W4385803022 cites W2083136610 @default.
• W4385803022 cites W2099516582 @default.
• W4385803022 cites W2132344035 @default.
• W4385803022 cites W2139476329 @default.
• W4385803022 cites W2154984288 @default.
• W4385803022 cites W2295608863 @default.
• W4385803022 cites W2626842659 @default.
• W4385803022 cites W2915827571 @default.
• W4385803022 cites W2968005098 @default.
• W4385803022 cites W2990740152 @default.
• W4385803022 cites W2994304950 @default.
• W4385803022 cites W3020657373 @default.
• W4385803022 cites W3106779259 @default.
• W4385803022 cites W3112344668 @default.
• W4385803022 cites W3136777525 @default.
• W4385803022 cites W3180442320 @default.
• W4385803022 cites W3200547044 @default.
• W4385803022 cites W4292810072 @default.
• W4385803022 doi "https://doi.org/10.1038/s41598-023-40239-w" @default.
• W4385803022 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37580421" @default.
• W4385803022 hasPublicationYear "2023" @default.
• W4385803022 type Work @default.
• W4385803022 citedByCount "0" @default.
• W4385803022 crossrefType "journal-article" @default.
• W4385803022 hasAuthorship W4385803022A5005059937 @default.
• W4385803022 hasAuthorship W4385803022A5010738468 @default.
• W4385803022 hasAuthorship W4385803022A5029839968 @default.
• W4385803022 hasAuthorship W4385803022A5032499914 @default.
• W4385803022 hasAuthorship W4385803022A5034185369 @default.
• W4385803022 hasAuthorship W4385803022A5035457024 @default.
• W4385803022 hasAuthorship W4385803022A5040485869 @default.
• W4385803022 hasAuthorship W4385803022A5077389488 @default.
• W4385803022 hasBestOaLocation W43858030221 @default.
• W4385803022 hasConcept C113067387 @default.
• W4385803022 hasConcept C126322002 @default.
• W4385803022 hasConcept C134018914 @default.
• W4385803022 hasConcept C154317977 @default.
• W4385803022 hasConcept C159654299 @default.
• W4385803022 hasConcept C185592680 @default.
• W4385803022 hasConcept C202751555 @default.
• W4385803022 hasConcept C203014093 @default.
• W4385803022 hasConcept C24998067 @default.
• W4385803022 hasConcept C2776090121 @default.
• W4385803022 hasConcept C2777385706 @default.
• W4385803022 hasConcept C2778297628 @default.
• W4385803022 hasConcept C2778957590 @default.
• W4385803022 hasConcept C2781101188 @default.
• W4385803022 hasConcept C39347974 @default.
• W4385803022 hasConcept C553184892 @default.
• W4385803022 hasConcept C55493867 @default.
• W4385803022 hasConcept C71924100 @default.
• W4385803022 hasConcept C8891405 @default.
• W4385803022 hasConceptScore W4385803022C113067387 @default.
• W4385803022 hasConceptScore W4385803022C126322002 @default.
• W4385803022 hasConceptScore W4385803022C134018914 @default.
• W4385803022 hasConceptScore W4385803022C154317977 @default.
• W4385803022 hasConceptScore W4385803022C159654299 @default.
• W4385803022 hasConceptScore W4385803022C185592680 @default.
• W4385803022 hasConceptScore W4385803022C202751555 @default.
• W4385803022 hasConceptScore W4385803022C203014093 @default.
• W4385803022 hasConceptScore W4385803022C24998067 @default.
• W4385803022 hasConceptScore W4385803022C2776090121 @default.
• W4385803022 hasConceptScore W4385803022C2777385706 @default.
• W4385803022 hasConceptScore W4385803022C2778297628 @default.
• W4385803022 hasConceptScore W4385803022C2778957590 @default.
• W4385803022 hasConceptScore W4385803022C2781101188 @default.
• W4385803022 hasConceptScore W4385803022C39347974 @default.
• W4385803022 hasConceptScore W4385803022C553184892 @default.
• W4385803022 hasConceptScore W4385803022C55493867 @default.
• W4385803022 hasConceptScore W4385803022C71924100 @default.
• W4385803022 hasConceptScore W4385803022C8891405 @default.
• W4385803022 hasFunder F4320321001 @default.
• W4385803022 hasIssue "1" @default.
• W4385803022 hasLocation W43858030221 @default.
• W4385803022 hasLocation W43858030222 @default.
• W4385803022 hasOpenAccess W4385803022 @default.
• W4385803022 hasPrimaryLocation W43858030221 @default.
• W4385803022 hasRelatedWork W2034768996 @default.
• W4385803022 hasRelatedWork W2054992011 @default.

• next